TOBY Gains FDA Breakthrough Status for MCED Test
AUSTIN, TEXAS, USA, April 14, 2026 TOBY, Inc. has received FDA Breakthrough Device Designation for its urine-based Multi-Cancer Early...
Oncology Diagnostics
Advertisement
NeoGenomics Advances AI-Driven Oncology Insights at AACR
Fort Myers, Florida | April 13, 2026 NeoGenomics, Inc. has announced the presentation of multiple scientific abstracts at the...
Saladax Expands Global Access to Drug Monitoring Tests
BETHLEHEM, PA, April 7, 2026 Saladax Biomedical, Inc. has announced a strategic distribution agreement with Thermo Fisher Scientific to...
Clarity Co-PSMA Shows Superior Prostate Cancer Detection
SYDNEY, Australia, March 31, 2026 Clarity Pharmaceuticals has announced the publication of Phase II Co-PSMA clinical trial results in...
Caris Detect Study Shows Strong Early Cancer Detection
IRVING, Texas, USA, March 31, 2026 Caris Life Sciences has announced final results from the Achieve 1 study, demonstrating...
Advertisements
mdxhealth Showcases GPS Test Advancing Prostate Care
Irvine, California, March 16, 2026 mdxhealth SA announced new clinical data from the ProMPT study led by the University...
FAPI-74 Phase 3 Trial Doses First Pancreatic Patient
DULLES, Va., Feb. 11, 2026 — SOFIE Biosciences announced that the first patient has been dosed in its Phase...
IBA Acquires ORA to Strengthen Nuclear Medicine Leadership
Louvain-La-Neuve, Belgium, December 19, 2025 — IBA (Ion Beam Applications S.A.), a global leader in particle accelerator technology and...
Natera Strengthens MRD Leadership With Acquisition of Foresight Diagnostics
AUSTIN, Texas — December 5, 2025 — Natera has announced the acquisition of Foresight Diagnostics, a precision oncology company...
Telo Genomics Unveils Single-Cell MRD Technology to Transform Myeloma Care
TORONTO, Ontario — November 13, 2025: Telo Genomics announced it will present its groundbreaking individual-cell MRD risk-assessment technology at...
Advertisement
